KR880004819A - 펩티드 제제 - Google Patents

펩티드 제제 Download PDF

Info

Publication number
KR880004819A
KR880004819A KR870011644A KR870011644A KR880004819A KR 880004819 A KR880004819 A KR 880004819A KR 870011644 A KR870011644 A KR 870011644A KR 870011644 A KR870011644 A KR 870011644A KR 880004819 A KR880004819 A KR 880004819A
Authority
KR
South Korea
Prior art keywords
insulin
range
derivative
value
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR870011644A
Other languages
English (en)
Korean (ko)
Inventor
홀거 요에르겐센 클라브스
Original Assignee
원본미기재
노보인두스트리 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK503386A external-priority patent/DK503386D0/da
Priority claimed from DK356987A external-priority patent/DK356987D0/da
Application filed by 원본미기재, 노보인두스트리 아크티에 셀스카브 filed Critical 원본미기재
Publication of KR880004819A publication Critical patent/KR880004819A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR870011644A 1986-10-20 1987-10-20 펩티드 제제 Ceased KR880004819A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK5033 1981-11-13
DK503386A DK503386D0 (da) 1986-10-20 1986-10-20 Peptidpraeparater
DK356987A DK356987D0 (enExample) 1987-07-10 1987-07-10
DK3569 1987-07-10

Publications (1)

Publication Number Publication Date
KR880004819A true KR880004819A (ko) 1988-06-27

Family

ID=26067111

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870011644A Ceased KR880004819A (ko) 1986-10-20 1987-10-20 펩티드 제제

Country Status (18)

Country Link
US (1) US5070186A (enExample)
EP (1) EP0265213B1 (enExample)
KR (1) KR880004819A (enExample)
CN (1) CN87107049A (enExample)
AU (1) AU616381B2 (enExample)
CA (1) CA1316819C (enExample)
DE (1) DE3778287D1 (enExample)
ES (1) ES2033871T3 (enExample)
FI (1) FI86254C (enExample)
GR (1) GR3004912T3 (enExample)
HU (1) HU201475B (enExample)
IE (1) IE60264B1 (enExample)
IL (1) IL84203A (enExample)
NO (1) NO170754C (enExample)
NZ (1) NZ222214A (enExample)
PH (1) PH23446A (enExample)
PT (1) PT85949B (enExample)
YU (1) YU46665B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20030078195A1 (en) * 2001-08-27 2003-04-24 Kristensen Lars Thougaard Cartridge and medical delivery system accommodating such cartridge
BR0317896A (pt) * 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
SG176314A1 (en) * 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
US20090023629A1 (en) * 2005-12-23 2009-01-22 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
PL2074141T3 (pl) 2006-09-22 2017-02-28 Novo Nordisk A/S Analogi insuliny oporne na proteazę
WO2008132229A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
SG11201506888VA (en) 2013-04-03 2015-09-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
CN105636979B (zh) 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
MA41138B1 (fr) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Formulation à rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20180169190A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2076082A (en) * 1935-04-08 1937-04-06 Nordisk Insulinlab Therapeutic product and process
US2179384A (en) * 1937-04-05 1939-11-07 Univ Alberta Therapeutic composition and process of making it
US2190134A (en) * 1939-06-09 1940-02-13 Norton Co Grinding machine
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2474729A (en) * 1945-01-03 1949-06-28 Rhone Poulenc Sa Insulin preparations
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
DK98342C (da) * 1959-06-16 1964-03-31 Henry Marinus Dr Christensen Fremgangsmåde til fremstilling af et insulinpræparat til peroral applikation.
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1426061A (en) * 1972-12-28 1976-02-25 Ici Ltd Polypeptides
US3856771A (en) * 1973-07-16 1974-12-24 Lilly Co Eli Process for manufacturing alkali metal or ammonium insulin
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
AU550068B2 (en) * 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production

Also Published As

Publication number Publication date
GR3004912T3 (enExample) 1993-04-28
HUT46232A (en) 1988-10-28
NZ222214A (en) 1989-11-28
NO170754B (no) 1992-08-24
YU191887A (en) 1989-04-30
PT85949A (en) 1987-11-01
FI86254C (fi) 1992-08-10
FI874596L (fi) 1988-04-21
NO874347L (no) 1988-04-21
DE3778287D1 (de) 1992-05-21
PH23446A (en) 1989-08-07
US5070186A (en) 1991-12-03
FI86254B (fi) 1992-04-30
PT85949B (pt) 1990-07-31
FI874596A0 (fi) 1987-10-19
CN87107049A (zh) 1988-07-06
YU46665B (sh) 1994-01-20
EP0265213B1 (en) 1992-04-15
EP0265213A2 (en) 1988-04-27
AU616381B2 (en) 1991-10-31
IE872799L (en) 1988-04-20
CA1316819C (en) 1993-04-27
IE60264B1 (en) 1994-06-29
EP0265213A3 (en) 1988-11-09
NO170754C (no) 1992-12-02
AU7990787A (en) 1988-04-21
IL84203A (en) 1993-04-04
HU201475B (en) 1990-11-28
ES2033871T3 (es) 1993-04-01
NO874347D0 (no) 1987-10-19

Similar Documents

Publication Publication Date Title
KR880004819A (ko) 펩티드 제제
KR950005324A (ko) 인슐린 제제
BR9714434A (pt) Formulações de interferon liquidas estáveis
KR850007378A (ko) 인터로이킨-2의 안정화 조성물의 제조방법
EP0217645A3 (en) Stable formulation of biologically active proteins for parenteral injection
ATE47715T1 (de) Stabile salze von sam mit polyanionen.
IE820536L (en) Stabilized insulin preparation
KR890015745A (ko) 수용액으로 존재하는 피록시캄의 제약 조성물 및 그의 제조방법
EP0203649A3 (en) Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis
KR950005325A (ko) 제약 조성물
KR910011151A (ko) 소, 돼지용 항병성사료 및 사료용 첨가물
KR920018076A (ko) 신규 폴리펩티드
GB1372812A (en) Cerebrospinal fluid control standard
BR9911372A (pt) Preparações pesticidas sob a forma de suspensão aquosa
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
PT1107750E (pt) Composicao farmaceutica, a base de carboplatina, com actividade anti-tumor
RU2001104352A (ru) Фармацевтическая композиция с противоопухолевой активностью на основе карбоплатина
ATE149354T1 (de) Pharmazeutische zusammensetzung von stabilisiertem (leu 13>-motilin-hse
GB1450598A (en) Insuling preparations
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
IE40985L (en) Insulin preparation.
AU3026589A (en) A solution of carboplatin
KR890003403A (ko) 당뇨병의 합병증을 예방하거나 치료하기 위한 제제
Sherman et al. Participation of the chemotactic system in regulating cell division in Escherichia coli
KR890011901A (ko) 동물 성장 촉진제

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19871020

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19920925

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19871020

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19950830

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19951115

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19950830

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I